FOCUS trial: results, potentialities and limits

Luca Saba, Antonella Balestrieri, Alessandra Serra, Raimondo Garau, Carola Politi, Pierleone Lucatelli, Alessandro Murgia, Jasjit S. Suri, Lorenzo Mannelli


In January 2019 Lancet has published the paper “Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial” (1). The main purpose of this prospective trial was to asses if fluoxetine [a selective serotonin reuptake inhibitor (SSRI) drug] could improve recovery after stroke.